LatchBio is a Cell Engineering & Bio-tools company founded in 2021 and based in San Francisco, United States. It has raised $33M in total funding, most recently a Series A in 2022.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Jun 2, 2022 | Series A | $28M | — | Coatue, Lux Capital |
No articles ingested yet for LatchBio. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
A cloud-based bioinformatics platform that lets life-science teams store, transform, analyze, and visualize large sequencing and multiomics datasets through a web interface. Scientists can run packaged, no-code analysis apps and reproducible pipelines on managed cloud compute without provisioning their own infrastructure, and developers can publish custom workflows. Used by wet-lab biologists and computational scientists at biotech and genomics organizations to move from raw instrument output to interpretable results faster.